This strategic analysis provides an in-depth evaluation of the Global Chronic Urticaria (CU) or Hives Drug Market for the forecast period 2026–2036. Chronic Urticaria, particularly Chronic Spontaneous Urticaria (CSU), represents a significant therapeutic challenge, driving a shift from standard antihistamines to advanced biologics and targeted oral therapies.
1. Market Overview & Executive Summary
The global Chronic Urticaria drug market is witnessing a paradigm shift. While H1-antihistamines remain the first-line treatment, a substantial percentage of patients are refractory to these drugs, creating a high-growth sector for second- and third-line therapies.
-
Market Growth: The market is projected to grow at a CAGR of 8.2% during 2026–2036.
-
Key Driver: The emergence of BTK (Bruton’s Tyrosine Kinase) inhibitors and next-generation monoclonal antibodies.
-
Base Year: 2025 | Forecast Period: 2026–2036.
2. Expanded Key Players
In addition to the legacy manufacturers, the following entities are pivotal in the current and future landscape:
-
Market Leaders: Novartis AG (Xolair), Genentech (Roche), AstraZeneca, GlaxoSmithKline (GSK).
-
Specialty & Pipeline Innovators:
-
Sanofi & Regeneron: (Dupixent/Dupilumab – expanding into CSU indications).
-
Celldex Therapeutics: (Barzolvolimab – a leader in KIT inhibitor research).
-
Amgen Inc.: (Developing biosimilars and novel inflammation inhibitors).
-
Celgene (Bristol Myers Squibb): Focused on immunomodulators.
-
Leo Pharma: Specialized in dermatological immunology.
-
Teva Pharmaceutical Industries: Focus on generic antihistamines and biosimilars.
-
Allakos Inc.: Developing lirentelimab for skin-related inflammatory mast cell disorders.
-
3. Segment Analysis
By Drug Class (Type)
-
Antihistamines (H1 & H2): Includes Bilastine, Loratadine, and Cetirizine. Remains the highest volume segment.
-
Biologics (Monoclonal Antibodies): Omalizumab (Xolair) is the gold standard, with new entrants like Ligelizumab and Dupilumab.
-
BTK Inhibitors: (e.g., Fenebrutinib/GDC-0853, Remibrutinib). This is the fastest-growing oral therapy segment.
-
Corticosteroids & Immunosuppressants: Used for short-term crisis management (e.g., Cyclosporine, Prednisone).
-
Leukotriene Receptor Antagonists: (e.g., Montelukast) often used as add-on therapy.
By Route of Administration
-
Oral: Preferred by patients for ease of use (Antihistamines and BTK inhibitors).
-
Injectable: Primarily biologics requiring clinical or self-administration.
By Application/Distribution Channel
-
Hospital Pharmacies: Primary channel for high-cost biologic initiations.
-
Retail Pharmacies: Dominant for OTC and maintenance prescription antihistamines.
-
Online Pharmacies: Rapidly growing due to the convenience of recurring prescriptions.
4. Regional Analysis
-
North America: The largest revenue contributor, driven by high treatment costs, favorable reimbursement for biologics, and rapid adoption of new FDA-approved drugs.
-
Europe: Focused on cost-effective care and the presence of major dermatology research hubs in Germany, France, and the UK.
-
Asia-Pacific: Expected to witness the highest CAGR. Factors include rising environmental pollution, increasing healthcare awareness in China and India, and the expansion of domestic biotech firms.
-
LAMEA: Growth is supported by improving healthcare infrastructure and localized manufacturing of generic antihistamines.
5. Porter’s Five Forces Analysis
-
Threat of New Entrants (Medium): High R&D costs for biologics act as a barrier, but the lucrative nature of the market attracts large-cap pharma.
-
Bargaining Power of Buyers (High): Insurance providers and government health bodies (NHS, etc.) exert significant pressure on the pricing of biologics.
-
Bargaining Power of Suppliers (Low): Raw materials for small-molecule antihistamines are commoditized.
-
Threat of Substitutes (Low-Medium): Limited alternative therapies exist for chronic cases, though dietary/lifestyle changes are often tried.
-
Competitive Rivalry (High): Intense competition between Novartis, Sanofi, and Roche to capture the "refractory patient" segment.
6. SWOT Analysis
| Strengths | Weaknesses |
| High patient adherence to chronic medication. | High cost of biologics limiting access in emerging markets. |
| Strong clinical pipeline for oral alternatives. | Side effects associated with long-term steroid use. |
| Opportunities | Threats |
| Expansion of "Omics" and precision medicine. | Impending patent expirations for key biologics. |
| Tele-dermatology increasing diagnosis rates. | Stringent regulatory pathways for new drug classes. |
7. Trend Analysis
-
Shift to Oral Biologics/Inhibitors: Patients are moving away from monthly injections toward daily oral BTK inhibitors.
-
Personalized Immunology: Using biomarkers to predict which patients will respond to anti-IgE vs. anti-IL-4/13 therapies.
-
Biosimilar Entry: As patents for early biologics expire, the entry of lower-cost biosimilars will democratize access to advanced treatment.
8. Drivers & Challenges
-
Driver: Rising Incidence: Increasing urban pollution and stress levels are linked to higher mast cell degranulation and urticaria flares.
-
Driver: Improved Diagnosis: Better clinical guidelines (EAACI/GA²LEN) have standardized the "step-up" treatment approach.
-
Challenge: Economic Burden: The high cost of chronic treatment poses a challenge for patients without comprehensive insurance.
-
Challenge: Heterogeneity: Chronic urticaria is highly variable; what works for one patient often fails for another, leading to high "churn" in drug prescriptions.
9. Value Chain Analysis
-
R&D & Molecular Discovery: Identification of mast cell pathways.
-
Clinical Trials: Phase I-III testing for safety and efficacy in CSU/CIndU.
-
Manufacturing: Specialized production of antibodies or high-purity chemical synthesis.
-
Logistics: Cold chain requirements for biologics.
-
Provider/Patient: Dermatologists and allergists acting as key gatekeepers.
10. Quick Recommendations for Stakeholders
-
For Pharma Manufacturers: Prioritize the development of oral BTK inhibitors. The market is trending toward "needle-free" chronic management.
-
For Investors: Look toward companies with strong Phase II/III data in KIT inhibitors or biosimilars for Omalizumab.
-
For Healthcare Providers: Leverage Digital Health tools for patient tracking (Urticaria Activity Score - UAS7) to justify the switch to advanced therapies for insurers.
-
For Retailers: Expand the OTC allergy segment with second-generation antihistamines (like Bilastine) as they gain broader regulatory approval.
Table of Contents
Global Chronic Urticaria Or Hives Drug Market Research Report 2026
1 Industry Overview of Chronic Urticaria Or Hives Drug
1.1 Definition and Specifications of Chronic Urticaria Or Hives Drug
1.1.1 Definition of Chronic Urticaria Or Hives Drug
1.1.2 Specifications of Chronic Urticaria Or Hives Drug
1.2 Classification of Chronic Urticaria Or Hives Drug
1.2.1 GDC-0853
1.2.2 GSK-2646264
1.2.3 BF-Derm-1
1.2.4 Bilastine
1.2.5 Others
1.3 Applications of Chronic Urticaria Or Hives Drug
1.3.1 Clinic
1.3.2 Hospital
1.3.3 Others
1.4 Market Segment by Regions
1.4.1 North America
1.4.2 Europe
1.4.3 China
1.4.4 Japan
1.4.5 Southeast Asia
1.4.6 India
2 Manufacturing Cost Structure Analysis of Chronic Urticaria Or Hives Drug
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Chronic Urticaria Or Hives Drug
2.3 Manufacturing Process Analysis of Chronic Urticaria Or Hives Drug
2.4 Industry Chain Structure of Chronic Urticaria Or Hives Drug
3 Technical Data and Manufacturing Plants Analysis of Chronic Urticaria Or Hives Drug
3.1 Capacity and Commercial Production Date of Global Chronic Urticaria Or Hives Drug Major Manufacturers
3.2 Manufacturing Plants Distribution of Global Chronic Urticaria Or Hives Drug Major Manufacturers
3.3 R&D Status and Technology Source of Global Chronic Urticaria Or Hives Drug Major Manufacturers
3.4 Raw Materials Sources Analysis of Global Chronic Urticaria Or Hives Drug Major Manufacturers
4 Global Chronic Urticaria Or Hives Drug Overall Market Overview
4.1 E Overall Market Analysis
4.2 Capacity Analysis
4.2.1 E Global Chronic Urticaria Or Hives Drug Capacity and Growth Rate Analysis
4.2.2 Chronic Urticaria Or Hives Drug Capacity Analysis (Company Segment)
4.3 Sales Analysis
4.3.1 E Global Chronic Urticaria Or Hives Drug Sales and Growth Rate Analysis
4.3.2 Chronic Urticaria Or Hives Drug Sales Analysis (Company Segment)
4.4 Sales Price Analysis
4.4.1 E Global Chronic Urticaria Or Hives Drug Sales Price
4.4.2 Chronic Urticaria Or Hives Drug Sales Price Analysis (Company Segment)
5 Chronic Urticaria Or Hives Drug Regional Market Analysis
5.1 North America Chronic Urticaria Or Hives Drug Market Analysis
5.1.1 North America Chronic Urticaria Or Hives Drug Market Overview
5.1.2 North America E Chronic Urticaria Or Hives Drug Local Supply, Import, Export, Local Consumption Analysis
5.1.3 North America E Chronic Urticaria Or Hives Drug Sales Price Analysis
5.1.4 North America Chronic Urticaria Or Hives Drug Market Share Analysis
5.2 Europe Chronic Urticaria Or Hives Drug Market Analysis
5.2.1 Europe Chronic Urticaria Or Hives Drug Market Overview
5.2.2 Europe E Chronic Urticaria Or Hives Drug Local Supply, Import, Export, Local Consumption Analysis
5.2.3 Europe E Chronic Urticaria Or Hives Drug Sales Price Analysis
5.2.4 Europe Chronic Urticaria Or Hives Drug Market Share Analysis
5.3 China Chronic Urticaria Or Hives Drug Market Analysis
5.3.1 China Chronic Urticaria Or Hives Drug Market Overview
5.3.2 China E Chronic Urticaria Or Hives Drug Local Supply, Import, Export, Local Consumption Analysis
5.3.3 China E Chronic Urticaria Or Hives Drug Sales Price Analysis
5.3.4 China Chronic Urticaria Or Hives Drug Market Share Analysis
5.4 Japan Chronic Urticaria Or Hives Drug Market Analysis
5.4.1 Japan Chronic Urticaria Or Hives Drug Market Overview
5.4.2 Japan E Chronic Urticaria Or Hives Drug Local Supply, Import, Export, Local Consumption Analysis
5.4.3 Japan E Chronic Urticaria Or Hives Drug Sales Price Analysis
5.4.4 Japan Chronic Urticaria Or Hives Drug Market Share Analysis
5.5 Southeast Asia Chronic Urticaria Or Hives Drug Market Analysis
5.5.1 Southeast Asia Chronic Urticaria Or Hives Drug Market Overview
5.5.2 Southeast Asia E Chronic Urticaria Or Hives Drug Local Supply, Import, Export, Local Consumption Analysis
5.5.3 Southeast Asia E Chronic Urticaria Or Hives Drug Sales Price Analysis
5.5.4 Southeast Asia Chronic Urticaria Or Hives Drug Market Share Analysis
5.6 India Chronic Urticaria Or Hives Drug Market Analysis
5.6.1 India Chronic Urticaria Or Hives Drug Market Overview
5.6.2 India E Chronic Urticaria Or Hives Drug Local Supply, Import, Export, Local Consumption Analysis
5.6.3 India E Chronic Urticaria Or Hives Drug Sales Price Analysis
5.6.4 India Chronic Urticaria Or Hives Drug Market Share Analysis
6 Global E Chronic Urticaria Or Hives Drug Segment Market Analysis (by Type)
6.1 Global E Chronic Urticaria Or Hives Drug Sales by Type
6.2 Different Types of Chronic Urticaria Or Hives Drug Product Interview Price Analysis
6.3 Different Types of Chronic Urticaria Or Hives Drug Product Driving Factors Analysis
6.3.1 GDC-0853 Growth Driving Factor Analysis
6.3.2 GSK-2646264 Growth Driving Factor Analysis
6.3.3 BF-Derm-1 Growth Driving Factor Analysis
6.3.4 Bilastine Growth Driving Factor Analysis
6.3.5 Others Growth Driving Factor Analysis
7 Global E Chronic Urticaria Or Hives Drug Segment Market Analysis (by Application)
7.1 Global E Chronic Urticaria Or Hives Drug Consumption by Application
7.2 Different Application of Chronic Urticaria Or Hives Drug Product Interview Price Analysis
7.3 Different Application of Chronic Urticaria Or Hives Drug Product Driving Factors Analysis
7.3.1 Clinic of Chronic Urticaria Or Hives Drug Growth Driving Factor Analysis
7.3.2 Hospital of Chronic Urticaria Or Hives Drug Growth Driving Factor Analysis
7.3.3 Others of Chronic Urticaria Or Hives Drug Growth Driving Factor Analysis
8 Major Manufacturers Analysis of Chronic Urticaria Or Hives Drug
8.1 AstraZeneca Plc
8.1.1 Company Profile
8.1.2 Product Picture and Specifications
8.1.2.1 Product A
8.1.2.2 Product B
8.1.3 AstraZeneca Plc Chronic Urticaria Or Hives Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.1.4 AstraZeneca Plc Chronic Urticaria Or Hives Drug Business Region Distribution Analysis
8.2 Biofrontera AG
8.2.1 Company Profile
8.2.2 Product Picture and Specifications
8.2.2.1 Product A
8.2.2.2 Product B
8.2.3 Biofrontera AG Chronic Urticaria Or Hives Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.2.4 Biofrontera AG Chronic Urticaria Or Hives Drug Business Region Distribution Analysis
8.3 ELORAC, Inc.
8.3.1 Company Profile
8.3.2 Product Picture and Specifications
8.3.2.1 Product A
8.3.2.2 Product B
8.3.3 ELORAC, Inc. Chronic Urticaria Or Hives Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.3.4 ELORAC, Inc. Chronic Urticaria Or Hives Drug Business Region Distribution Analysis
8.4 Faes Farma, SA
8.4.1 Company Profile
8.4.2 Product Picture and Specifications
8.4.2.1 Product A
8.4.2.2 Product B
8.4.3 Faes Farma, SA Chronic Urticaria Or Hives Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.4.4 Faes Farma, SA Chronic Urticaria Or Hives Drug Business Region Distribution Analysis
8.5 Genentech, Inc.
8.5.1 Company Profile
8.5.2 Product Picture and Specifications
8.5.2.1 Product A
8.5.2.2 Product B
8.5.3 Genentech, Inc. Chronic Urticaria Or Hives Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.5.4 Genentech, Inc. Chronic Urticaria Or Hives Drug Business Region Distribution Analysis
8.6 GlaxoSmithKline Plc
8.6.1 Company Profile
8.6.2 Product Picture and Specifications
8.6.2.1 Product A
8.6.2.2 Product B
8.6.3 GlaxoSmithKline Plc Chronic Urticaria Or Hives Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.6.4 GlaxoSmithKline Plc Chronic Urticaria Or Hives Drug Business Region Distribution Analysis
8.7 J Uriach Y Compania, S.A.
8.7.1 Company Profile
8.7.2 Product Picture and Specifications
8.7.2.1 Product A
8.7.2.2 Product B
8.7.3 J Uriach Y Compania, S.A. Chronic Urticaria Or Hives Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.7.4 J Uriach Y Compania, S.A. Chronic Urticaria Or Hives Drug Business Region Distribution Analysis
8.8 Mabtech Limited
8.8.1 Company Profile
8.8.2 Product Picture and Specifications
8.8.2.1 Product A
8.8.2.2 Product B
8.8.3 Mabtech Limited Chronic Urticaria Or Hives Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.8.4 Mabtech Limited Chronic Urticaria Or Hives Drug Business Region Distribution Analysis
8.9 Merck & Co., Inc.
8.9.1 Company Profile
8.9.2 Product Picture and Specifications
8.9.2.1 Product A
8.9.2.2 Product B
8.9.3 Merck & Co., Inc. Chronic Urticaria Or Hives Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.9.4 Merck & Co., Inc. Chronic Urticaria Or Hives Drug Business Region Distribution Analysis
8.10 Mycenax Biotech Inc.
8.10.1 Company Profile
8.10.2 Product Picture and Specifications
8.10.2.1 Product A
8.10.2.2 Product B
8.10.3 Mycenax Biotech Inc. Chronic Urticaria Or Hives Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.10.4 Mycenax Biotech Inc. Chronic Urticaria Or Hives Drug Business Region Distribution Analysis
8.11 Novartis AG
8.12 Panacea Biotec Limited
9 Development Trend of Analysis of Chronic Urticaria Or Hives Drug Market
9.1 Global Chronic Urticaria Or Hives Drug Market Trend Analysis
9.1.1 Global 2018-2025 Chronic Urticaria Or Hives Drug Market Size (Volume and Value) Forecast
9.1.2 Global 2018-2025 Chronic Urticaria Or Hives Drug Sales Price Forecast
9.2 Chronic Urticaria Or Hives Drug Regional Market Trend
9.2.1 North America 2018-2025 Chronic Urticaria Or Hives Drug Consumption Forecast
9.2.2 Europe 2018-2025 Chronic Urticaria Or Hives Drug Consumption Forecast
9.2.3 China 2018-2025 Chronic Urticaria Or Hives Drug Consumption Forecast
9.2.4 Japan 2018-2025 Chronic Urticaria Or Hives Drug Consumption Forecast
9.2.5 Southeast Asia 2018-2025 Chronic Urticaria Or Hives Drug Consumption Forecast
9.2.6 India 2018-2025 Chronic Urticaria Or Hives Drug Consumption Forecast
9.3 Chronic Urticaria Or Hives Drug Market Trend (Product Type)
9.4 Chronic Urticaria Or Hives Drug Market Trend (Application)
10 Chronic Urticaria Or Hives Drug Marketing Type Analysis
10.1 Chronic Urticaria Or Hives Drug Regional Marketing Type Analysis
10.2 Chronic Urticaria Or Hives Drug International Trade Type Analysis
10.3 Traders or Distributors with Contact Information of Chronic Urticaria Or Hives Drug by Region
10.4 Chronic Urticaria Or Hives Drug Supply Chain Analysis
11 Consumers Analysis of Chronic Urticaria Or Hives Drug
11.1 Consumer 1 Analysis
11.2 Consumer 2 Analysis
11.3 Consumer 3 Analysis
11.4 Consumer 4 Analysis
12 Conclusion of the Global Chronic Urticaria Or Hives Drug Market Professional Survey Report
Methodology
Analyst Introduction
Data Source
List of Tables and Figures
Figure Picture of Chronic Urticaria Or Hives Drug
Table Product Specifications of Chronic Urticaria Or Hives Drug
Table Classification of Chronic Urticaria Or Hives Drug
Figure Global Production Market Share of Chronic Urticaria Or Hives Drug by Type in
Figure GDC-0853 Picture
Table Major Manufacturers of GDC-0853
Figure GSK-2646264 Picture
Table Major Manufacturers of GSK-2646264
Figure BF-Derm-1 Picture
Table Major Manufacturers of BF-Derm-1
Figure Bilastine Picture
Table Major Manufacturers of Bilastine
Figure Others Picture
Table Major Manufacturers of Others
Table Applications of Chronic Urticaria Or Hives Drug
Figure Global Consumption Volume Market Share of Chronic Urticaria Or Hives Drug by Application in
Figure Clinic Examples
Table Major Consumers in Clinic
Figure Hospital Examples
Table Major Consumers in Hospital
Figure Others Examples
Table Major Consumers in Others
Figure Market Share of Chronic Urticaria Or Hives Drug by Regions
Figure North America Chronic Urticaria Or Hives Drug Market Size (Million USD) (2013-2025)
Figure Europe Chronic Urticaria Or Hives Drug Market Size (Million USD) (2013-2025)
Figure China Chronic Urticaria Or Hives Drug Market Size (Million USD) (2013-2025)
Figure Japan Chronic Urticaria Or Hives Drug Market Size (Million USD) (2013-2025)
Figure Southeast Asia Chronic Urticaria Or Hives Drug Market Size (Million USD) (2013-2025)
Figure India Chronic Urticaria Or Hives Drug Market Size (Million USD) (2013-2025)
Table Chronic Urticaria Or Hives Drug Raw Material and Suppliers
Table Manufacturing Cost Structure Analysis of Chronic Urticaria Or Hives Drug in
Figure Manufacturing Process Analysis of Chronic Urticaria Or Hives Drug
Figure Industry Chain Structure of Chronic Urticaria Or Hives Drug
Table Capacity and Commercial Production Date of Global Chronic Urticaria Or Hives Drug Major Manufacturers
Table Manufacturing Plants Distribution of Global Chronic Urticaria Or Hives Drug Major Manufacturers
Table R&D Status and Technology Source of Global Chronic Urticaria Or Hives Drug Major Manufacturers
Table Raw Materials Sources Analysis of Global Chronic Urticaria Or Hives Drug Major Manufacturers
Table Global Capacity, Sales , Price, Cost, Sales Revenue (M USD) and Gross Margin of Chronic Urticaria Or Hives Drug E
Figure Global E Chronic Urticaria Or Hives Drug Market Size (Volume) and Growth Rate
Figure Global E Chronic Urticaria Or Hives Drug Market Size (Value) and Growth Rate
Table E Global Chronic Urticaria Or Hives Drug Capacity and Growth Rate
Table Global Chronic Urticaria Or Hives Drug Capacity (K Pcs) List (Company Segment)
Table E Global Chronic Urticaria Or Hives Drug Sales (K Pcs) and Growth Rate
Table Global Chronic Urticaria Or Hives Drug Sales (K Pcs) List (Company Segment)
Table E Global Chronic Urticaria Or Hives Drug Sales Price (USD/Pcs)
Table Global Chronic Urticaria Or Hives Drug Sales Price (USD/Pcs) List (Company Segment)
Figure North America Capacity Overview
Table North America Supply, Import, Export and Consumption (K Pcs) of Chronic Urticaria Or Hives Drug E
Figure North America E Chronic Urticaria Or Hives Drug Sales Price (USD/Pcs)
Figure North America Chronic Urticaria Or Hives Drug Sales Market Share
Figure Europe Capacity Overview
Table Europe Supply, Import, Export and Consumption (K Pcs) of Chronic Urticaria Or Hives Drug E
Figure Europe E Chronic Urticaria Or Hives Drug Sales Price (USD/Pcs)
Figure Europe Chronic Urticaria Or Hives Drug Sales Market Share
Figure China Capacity Overview
Table China Supply, Import, Export and Consumption (K Pcs) of Chronic Urticaria Or Hives Drug E
Figure China E Chronic Urticaria Or Hives Drug Sales Price (USD/Pcs)
Figure China Chronic Urticaria Or Hives Drug Sales Market Share
Figure Japan Capacity Overview
Table Japan Supply, Import, Export and Consumption (K Pcs) of Chronic Urticaria Or Hives Drug E
Figure Japan E Chronic Urticaria Or Hives Drug Sales Price (USD/Pcs)
Figure Japan Chronic Urticaria Or Hives Drug Sales Market Share
Figure Southeast Asia Capacity Overview
Table Southeast Asia Supply, Import, Export and Consumption (K Pcs) of Chronic Urticaria Or Hives Drug E
Figure Southeast Asia E Chronic Urticaria Or Hives Drug Sales Price (USD/Pcs)
Figure Southeast Asia Chronic Urticaria Or Hives Drug Sales Market Share
Figure India Capacity Overview
Table India Supply, Import, Export and Consumption (K Pcs) of Chronic Urticaria Or Hives Drug E
Figure India E Chronic Urticaria Or Hives Drug Sales Price (USD/Pcs)
Figure India Chronic Urticaria Or Hives Drug Sales Market Share
Table Global E Chronic Urticaria Or Hives Drug Sales (K Pcs) by Type
Table Different Types Chronic Urticaria Or Hives Drug Product Interview Price
Table Global E Chronic Urticaria Or Hives Drug Sales (K Pcs) by Application
Table Different Application Chronic Urticaria Or Hives Drug Product Interview Price
Table AstraZeneca Plc Information List
Table Product Overview
Table AstraZeneca Plc Chronic Urticaria Or Hives Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure AstraZeneca Plc Chronic Urticaria Or Hives Drug Business Region Distribution
Table Biofrontera AG Information List
Table Product Overview
Table Biofrontera AG Chronic Urticaria Or Hives Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Biofrontera AG Chronic Urticaria Or Hives Drug Business Region Distribution
Table ELORAC, Inc. Information List
Table Product Overview
Table ELORAC, Inc. Chronic Urticaria Or Hives Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure ELORAC, Inc. Chronic Urticaria Or Hives Drug Business Region Distribution
Table Faes Farma, SA Information List
Table Product Overview
Table Faes Farma, SA Chronic Urticaria Or Hives Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Faes Farma, SA Chronic Urticaria Or Hives Drug Business Region Distribution
Table Genentech, Inc. Information List
Table Product Overview
Table Genentech, Inc. Chronic Urticaria Or Hives Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Genentech, Inc. Chronic Urticaria Or Hives Drug Business Region Distribution
Table GlaxoSmithKline Plc Information List
Table Product Overview
Table GlaxoSmithKline Plc Chronic Urticaria Or Hives Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure GlaxoSmithKline Plc Chronic Urticaria Or Hives Drug Business Region Distribution
Table J Uriach Y Compania, S.A. Information List
Table Product Overview
Table J Uriach Y Compania, S.A. Chronic Urticaria Or Hives Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure J Uriach Y Compania, S.A. Chronic Urticaria Or Hives Drug Business Region Distribution
Table Mabtech Limited Information List
Table Product Overview
Table Mabtech Limited Chronic Urticaria Or Hives Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Mabtech Limited Chronic Urticaria Or Hives Drug Business Region Distribution
Table Merck & Co., Inc. Information List
Table Product Overview
Table Merck & Co., Inc. Chronic Urticaria Or Hives Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Merck & Co., Inc. Chronic Urticaria Or Hives Drug Business Region Distribution
Table Mycenax Biotech Inc. Information List
Table Product Overview
Table Mycenax Biotech Inc. Chronic Urticaria Or Hives Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Mycenax Biotech Inc. Chronic Urticaria Or Hives Drug Business Region Distribution
Table Novartis AG Information List
Table Panacea Biotec Limited Information List
Figure Global 2018-2025 Chronic Urticaria Or Hives Drug Market Size (K Pcs) and Growth Rate Forecast
Figure Global 2018-2025 Chronic Urticaria Or Hives Drug Market Size (Million USD) and Growth Rate Forecast
Figure Global 2018-2025 Chronic Urticaria Or Hives Drug Sales Price (USD/Pcs) Forecast
Figure North America 2018-2025 Chronic Urticaria Or Hives Drug Consumption Volume (K Pcs) and Growth Rate Forecast
Figure China 2018-2025 Chronic Urticaria Or Hives Drug Consumption Volume (K Pcs) and Growth Rate Forecast
Figure Europe 2018-2025 Chronic Urticaria Or Hives Drug Consumption Volume (K Pcs) and Growth Rate Forecast
Figure Southeast Asia 2018-2025 Chronic Urticaria Or Hives Drug Consumption Volume (K Pcs) and Growth Rate Forecast
Figure Japan 2018-2025 Chronic Urticaria Or Hives Drug Consumption Volume (K Pcs) and Growth Rate Forecast
Figure India 2018-2025 Chronic Urticaria Or Hives Drug Consumption Volume (K Pcs) and Growth Rate Forecast
Table Global Sales Volume (K Pcs) of Chronic Urticaria Or Hives Drug by Type 2018-2025
Table Global Consumption Volume (K Pcs) of Chronic Urticaria Or Hives Drug by Application 2018-2025
Table Traders or Distributors with Contact Information of Chronic Urticaria Or Hives Drug by Region
Expanded Key Players
In addition to the legacy manufacturers, the following entities are pivotal in the current and future landscape:
-
Market Leaders: Novartis AG (Xolair), Genentech (Roche), AstraZeneca, GlaxoSmithKline (GSK).
-
Specialty & Pipeline Innovators:
-
Sanofi & Regeneron: (Dupixent/Dupilumab – expanding into CSU indications).
-
Celldex Therapeutics: (Barzolvolimab – a leader in KIT inhibitor research).
-
Amgen Inc.: (Developing biosimilars and novel inflammation inhibitors).
-
Celgene (Bristol Myers Squibb): Focused on immunomodulators.
-
Leo Pharma: Specialized in dermatological immunology.
-
Teva Pharmaceutical Industries: Focus on generic antihistamines and biosimilars.
-
Allakos Inc.: Developing lirentelimab for skin-related inflammatory mast cell disorders.
-
3. Segment Analysis
By Drug Class (Type)
-
Antihistamines (H1 & H2): Includes Bilastine, Loratadine, and Cetirizine. Remains the highest volume segment.
-
Biologics (Monoclonal Antibodies): Omalizumab (Xolair) is the gold standard, with new entrants like Ligelizumab and Dupilumab.
-
BTK Inhibitors: (e.g., Fenebrutinib/GDC-0853, Remibrutinib). This is the fastest-growing oral therapy segment.
-
Corticosteroids & Immunosuppressants: Used for short-term crisis management (e.g., Cyclosporine, Prednisone).
-
Leukotriene Receptor Antagonists: (e.g., Montelukast) often used as add-on therapy.
By Route of Administration
-
Oral: Preferred by patients for ease of use (Antihistamines and BTK inhibitors).
-
Injectable: Primarily biologics requiring clinical or self-administration.
By Application/Distribution Channel
-
Hospital Pharmacies: Primary channel for high-cost biologic initiations.
-
Retail Pharmacies: Dominant for OTC and maintenance prescription antihistamines.
-
Online Pharmacies: Rapidly growing due to the convenience of recurring prescriptions.
